Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Intranasal COVID-19 vaccines could be on the horizon

By Brian Buntz | March 8, 2021

AltImmune

Image courtesy of AltImmune

All of the COVID-19 vaccines authorized to date are delivered via intramuscular injection. But the intranasal vaccines that are now in development could lead to a more diverse vaccine landscape.

The company Altimmune (Gaithersburg, Md.) recently launched a Phase 1 clinical trial to test its single-dose adCOVID intranasal vaccine in 180 adult volunteers. Bharat Biotech (Hyderabad, India) is launching its own tests. In Europe, a newly-founded company known as Rokote Laboratories (Joensuu, Finland) is doing the same.

Intranasal vaccines could offer key advantages over intramuscular vaccines, said Dr. C. Buddy Creech, a professor within the Division of Pediatric Infectious Diseases at the Vanderbilt University School of Medicine.

[Related: Why intranasal vaccines can confer immunity where it matters]

First, an intranasal vaccine could trigger a broad immune response that includes both systemic immunity and local immunity in the respiratory tract. “Biologically, it makes sense,” Creech said. “We’d want to have a great deal of immunity at the actual site of where an infection starts.” For respiratory viruses such as COVID-19 typically first gain a foothold  in the nose and in the throat. Generating mucosal immunity would be an advantage of the intranasal approval. And such a vaccine could also potentially offer strong protection against slightly different variations of the virus.

“There’s a lot of potential,” Creech said. But there are few examples of highly effective intranasal vaccines apart from the FluMist live attenuated influenza vaccine.

When asked whether an intranasal vaccine could reduce the need for mask-wearing in the long run, given its potential to stimulate mucosal immunity, Creech demurred.

In general, data related to COVID-19 vaccines’ impact on transmission are sparse. “It stands to reason that if you don’t get disease or high fever and if you you’re not sick for as long, you’re not going to spread as much virus,” Creech said.

Intranasal vaccines, however, could enable more people to get vaccinated, which in turn, could reduce the emergence of new variants. Ultimately, the quality and quantity of population immunity will be what enables society to relax COVID-19 mitigation measures. “The goal here is not to eradicate this virus necessarily,” Creech said. “The goal is to turn it into a common cold virus. And the way we do that is we generate a lot of immunity,” he added. “So I guess I bring that up to say it’s a tall order to require a vaccine to prevent transmission altogether — whether that vaccine is in the muscle or just under the skin or an intranasal vaccine.”


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development, Infectious Disease
Tagged With: coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, intranasal vaccine
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE